丙戊茶碱(Propentofylline) - 药物靶点：cGMP-PDE_在研适应症：脑血管疾病，胶质母细胞瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Hextol、Propentofylline (JAN/INN)、Viviq

+ [5]

靶点

cGMP-PDE

作用机制

cGMP-PDE抑制剂(cGMP-磷酸二酯酶抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Oleolive, Inc.初创企业

Sanofi

非在研机构

Hoechst Pakistan Ltd.

最高研发阶段批准上市

首次获批日期

韩国 (1997-10-30),

脑血管疾病

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C15H22N4O3

InChIKeyRBQOQRRFDPXAGN-UHFFFAOYSA-N

CAS号55242-55-2

关联

1

项与丙戊茶碱相关的临床试验

IRCT20090117001556N113 / Recruiting临床3期IIT

Effect of propentofylline add on therapy to risperidon in children with autism: a randomized double-blind placebo-controlled clinical trial

开始日期2018-11-22

申办/合作机构

Tehran University of Medical Sciences

100 项与丙戊茶碱相关的临床结果

登录后查看更多信息

100 项与丙戊茶碱相关的转化医学

登录后查看更多信息

100 项与丙戊茶碱相关的专利（医药）

登录后查看更多信息

269

项与丙戊茶碱相关的文献（医药）

2024-01-02·Expert Opinion on Emerging Drugs

Emerging drugs for the treatment of irritability associated with autism spectrum disorder

Review

作者: Akhondzadeh, Shahin ; Motavaselian, Mohsen ; Shamabadi, Ahmad ; Arabzadeh Bahri, Razman ; Karimi, Hanie

INTRODUCTIONAutism spectrum disorder (ASD) is an early-onset disorder with a prevalence of 1% among children and reported disability-adjusted life years of 4.31 million. Irritability is a challenging behavior associated with ASD, for which medication development has lagged. More specifically, pharmacotherapy effectiveness may be limited against high adverse effects (considering side effect profiles and patient medication sensitivity); thus, the possible benefits of pharmacological interventions must be balanced against potential adverse events in each patient.AREAS COVEREDAfter reviewing the neuropathophysiology of ASD-associated irritability, the benefits and tolerability of emerging medications in its treatment based on randomized controlled trials were detailed in light of mechanisms and targets of action.EXPERT OPINIONSucceeding risperidone and aripiprazole, monotherapy with memantine may be beneficial. In addition, N-acetylcysteine, galantamine, sulforaphane, celecoxib, palmitoylethanolamide, pentoxifylline, simvastatin, minocycline, amantadine, pregnenolone, prednisolone, riluzole, propentofylline, pioglitazone, and topiramate, all adjunct to risperidone, and clonidine and methylphenidate outperformed placebo. These effects were through glutamatergic, γ-aminobutyric acidergic, inflammatory, oxidative, cholinergic, dopaminergic, and serotonergic systems. All medications were reported to be safe and tolerable. Considering sample size, follow-up, and effect size, further studies are necessary. Along with drug development, repositioning and combining existing drugs supported by the mechanism of action is recommended.

2023-06-07·Biomedicines

Propentofylline Improves Thiol-Based Antioxidant Defenses and Limits Lipid Peroxidation following Gliotoxic Injury in the Rat Brainstem.

Article

作者: Guariroba, Maísa ; Vardaris, Cristina V ; Pereira, Álvaro A F ; Barros, Marcelo P ; Martins, Maria F ; Poppe, Sandra C ; Bondan, Eduardo F ; Baliellas, Deborah E M

Propentofylline (PROP) is a methylated xanthine compound that diminishes the activation of microglial cells and astrocytes, which are neuronal cells strongly associated with many neurodegenerative diseases. Based on previously observed remyelination and neuroprotective effects, PROP has also been proposed to increment antioxidant defenses and to prevent oxidative damage in neural tissues. Since most neurodegenerative processes have free radicals as molecular pathological agents, the aim of this study was to evaluate the antioxidant effects of 12.5 mg·kg^-1·day^-1 PROP in plasma and the brainstem of Wistar rats exposed to the gliotoxic agent 0.1% ethidium bromide (EB) for 7-31 days. The bulk of the data here demonstrates that, after 7 days of EB treatment, TBARS levels were 2-fold higher in the rat CNS than in control, reaching a maximum of 2.4-fold within 15 days. After 31 days of EB treatment, lipoperoxidation in CNS was still 65% higher than that in the control. Clearly, PROP treatment limited the progression of lipoperoxidation in EB-oxidized CNS: it was, for example, 76% lower than in the EB-treated group after 15 days. Most of these effects were associated with PROP-induced activity of glutathione reductase in the brainstem: the EB + PROP group showed 59% higher GR activity than that of the EB or control groups within 7 days. In summary, aligning with previous studies from our group and with literature about MTXs, we observed that propentofylline (PROP) improved the thiol-based antioxidant defenses in the rat brainstem by the induction of the enzymatic activity of glutathione reductase (GR), which diminished lipid oxidation progression and rebalanced the redox status in the CNS.

2021-01-01·Veterinary Record3区 · 农林科学

Cognitive Dysfunction in Cats: Update on Neuropathological and Behavioural Changes Plus Clinical Management

3区 · 农林科学

Review

作者: Gunn‐Moore, Danièlle A. ; Sordo, Lorena

AbstractCognitive dysfunction syndrome (CDS) is an established condition in cats that shares many similarities with human Alzheimer's disease (AD), where cognitive decline ultimately results in dementia. Cats with CDS display behavioural abnormalities, including excessive Vocalisation, altered Interaction with owners (increased affection/attention), altered Sleep‐wake cycles, House‐soiling, Disorientation (spatial and/or temporal), alterations in Activity, Anxiety, and/or Learning/memory deficits (i.e., VISHDAAL). These cats develop neuropathologies, such as accumulation ofβ‐amyloid and hyperphosphorylated tau deposits. Because of its similarities to those in the brains of people with cognitive impairment and AD, the domestic cat could be a natural model for human dementia studies. It is important to diagnose CDS promptly in cats, ruling out other causes for these behavioural changes, to provide effective management. Interventions include environmental enrichment (e.g., easy access to key resources, calming pheromones), dietary supplementations (e.g., Senilife, Aktivait for cats, SAMe), specific diets (e.g., containing antioxidants, medium‐chain triglycerides) and, potentially, medication (e.g., selegiline or propentofylline). This article reviews the literature about CDS in cats, its causes, neuropathology, clinical signs, diagnosis and potential management options. By doing so, it furthers our understanding of this condition and allows improved health, welfare and quality of life of affected cats.

1

项与丙戊茶碱相关的新闻（医药）

2022-09-08

·PRNewswire

Entrepreneurial Accelerator Program (EAP) Portfolio Company receives $400,000 Research Grant from The National Cancer Institute to study a repurposed drug in treatment of Glioblastoma

SHREVEPORT, La., Sept. 8, 2022 /PRNewswire/ -- Entrepreneurial Accelerator Program (EAP) portfolio company Oleolive, Inc. has been awarded a Small Business Technology Transfer (STTR) Phase 1 $400,000 research grant from the National Cancer Institute for "Chemosensitization of Glioblastoma by Propentofylline." Drs. Nhan Tran and Joseph Loftus, investigators at Mayo Clinic and experts in Glioblastoma Multiforme (GBM), collaborated with Oleolive on the proposal. Propentofylline (PPF) was originally tested in multiple clinical trials for Alzheimer's disease but, although shown to be safe and effective, was not brought to the commercial market. PPF is considered a repurposed drug, defined as a drug developed for one indication and repositioned to treat another, in this case GBM. Repurposed drugs require less money and time for development and overall costs much less compared to research and development of new drugs. GBM is a brain cancer with no effective therapeutics that claims the lives of over 15,000 Americans each year. GBM has poor clinical outcomes due to therapy-resistant tumor cells leading to recurrence; therefore, therapeutic strategies that enhance tumor cell chemosensitivity are essential for improved patient outcomes. This project will evaluate if PPF increases sensitization of GBM tumor cells to chemotherapy. This research could lead to a therapeutic strategy to extend survival for GBM patients beyond the current average of 1.25 years. About Oleolive, Inc . Oleolive, Inc. is a preclinical private biotechnology company founded in 2017, located in Shreveport, Louisiana. The company is developing therapeutics to treat a variety of human indications, including brain cancer, Alzheimer's disease, fibrosis, and traumatic blood loss in austere environments. The company has received more than $5M in STTRs and small business innovation research (SBIR) grant awards from multiple funding sources including the National Institute on Aging, the National Cancer Institute, the National Heart, Lung, and Blood Institute and the Department of Defense. Oleolive also manufactures the dietary ingredient Oligen which contains compounds from Extra Virgin Olive Oil that promote healthy aging. To learn more about Oleolive, Inc. please visit our website , or contact [email protected] with inquiries. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R41CA268286. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SOURCE Entrepreneurial Accelerator Program

小分子药物合作

100 项与丙戊茶碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01630	丙戊茶碱	N06BC02	DB06479

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
脑血管疾病	韩国	Sanofi	1997-10-30

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床2期	加拿大	Hoechst Pakistan Ltd.	-
血管性痴呆	临床2期	欧盟	Hoechst Pakistan Ltd.	-
血管性痴呆	临床2期	加拿大	Hoechst Pakistan Ltd.	-
胶质母细胞瘤	临床前	美国	Oleolive, Inc.初创企业	2022-11-17
阿尔茨海默症	临床前	欧盟	Hoechst Pakistan Ltd.	-